--- type: "Topics" locale: "en" url: "https://longbridge.com/en/topics/100000000948323.md" description: "๐Ÿ“ข ๐—๐—จ๐—ฆ๐—ง ๐—œ๐—ก: $ImmunityBio(IBRX.US) ImmunityBio Completes Phase 3 ANKTIVA Trial Database Lock, Targets November Results and Q4 FDA Filing๐Ÿ‘‰ ๐—ž๐—ฒ๐˜† ๐—›๐—ถ๐—ด๐—ต๐—น๐—ถ๐—ด๐—ต๐˜๐˜€:โžค ๐—œ๐—บ๐—บ๐˜‚๐—ป๐—ถ๐˜๐˜†๐—•๐—ถ๐—ผ (๐—œ๐—•๐—ฅ๐—ซ) completes ๐—ค๐—จ๐—œ๐—Ÿ๐—ง-๐Ÿฎ.๐Ÿฌ๐Ÿฌ๐Ÿฑ Cohort A database lock.โžค Trial includes ๐Ÿฏ๐Ÿฒ๐Ÿฒ randomized patients across ๐Ÿญ๐Ÿญ๐Ÿฌ global clinical sites.โžค Study compares ๐—”๐—ก๐—ž๐—ง๐—œ๐—ฉ๐—” ๐—ฝ๐—น๐˜‚๐˜€ ๐—•๐—–๐—š against BCG alone.โžค Targets ๐—•๐—–๐—š-๐—ป๐—ฎรฏ๐˜ƒ๐—ฒ non-muscle invasive bladder cancer patients.โžค Previous interim analysis demonstrated ๐˜€๐˜๐—ฎ๐˜๐—ถ๐˜€๐˜๐—ถ๐—ฐ๐—ฎ๐—น๐—น๐˜† ๐˜€๐—ถ๐—ด๐—ป๐—ถ๐—ณ๐—ถ๐—ฐ๐—ฎ๐—ป๐˜๐—น๐˜† longer complete response duration.โžค Independent monitoring committee confirmed ๐—ป๐—ผ ๐—ฎ๐—ฑ๐—ฑ๐—ถ๐˜๐—ถ๐—ผ๐—ป๐—ฎ๐—น ๐—ฒ๐—ป๐—ฟ๐—ผ๐—น๐—น๐—บ๐—ฒ๐—ป๐˜ was required.โžค Final analysis will evaluate ๐—ฐ๐—ผ๐—บ๐—ฝ๐—น๐—ฒ๐˜๐—ฒ ๐—ฟ๐—ฒ๐˜€๐—ฝ๐—ผ๐—ป๐˜€๐—ฒ ๐—ฟ๐—ฎ๐˜๐—ฒ๐˜€ and durability.โžค ImmunityBio expects ๐˜๐—ผ๐—ฝ๐—น๐—ถ๐—ป๐—ฒ ๐—ฟ๐—ฒ๐˜€๐˜‚๐—น๐˜๐˜€ in ๐—ก๐—ผ๐˜ƒ๐—ฒ๐—บ๐—ฏ๐—ฒ๐—ฟ ๐Ÿฎ๐Ÿฌ๐Ÿฎ๐Ÿฒ.โžค Company targets ๐—™๐——๐—” ๐˜€๐—•๐—Ÿ๐—” ๐˜€๐˜‚๐—ฏ๐—บ๐—ถ๐˜€๐˜€๐—ถ๐—ผ๐—ป in ๐—ค๐Ÿฐ ๐Ÿฎ๐Ÿฌ๐Ÿฎ๐Ÿฒ.โžค Potential approval could expand ANKTIVA treatment to ๐—ฒ๐—ฎ๐—ฟ๐—น๐—ถ๐—ฒ๐—ฟ-๐˜€๐˜๐—ฎ๐—ด๐—ฒ bladder cancer patients.๐Ÿ‘‰ ๐—ช๐—ต๐˜† ๐—ง๐—ต๐—ถ๐˜€ ๐— ๐—ฎ๐˜๐˜๐—ฒ๐—ฟ๐˜€:โžค Database lock represents a ๐—บ๐—ฎ๐—ท๐—ผ๐—ฟ ๐—ฟ๐—ฒ๐—ด๐˜‚๐—น๐—ฎ๐˜๐—ผ๐—ฟ๐˜† ๐—บ๐—ถ๐—น๐—ฒ๐˜€๐˜๐—ผ๐—ป๐—ฒ ahead of final analysis.โžค Positive results could significantly expand ๐—”๐—ก๐—ž๐—ง๐—œ๐—ฉ๐—”'๐˜€ ๐—ฎ๐—ฑ๐—ฑ๐—ฟ๐—ฒ๐˜€๐˜€๐—ฎ๐—ฏ๐—น๐—ฒ ๐—ฝ๐—ฎ๐˜๐—ถ๐—ฒ๐—ป๐˜ ๐—ฝ๐—ผ๐—ฝ๐˜‚๐—น๐—ฎ๐˜๐—ถ๐—ผ๐—ป.โžค November data and Q4 FDA filing represent ๐—ธ๐—ฒ๐˜† ๐—ป๐—ฒ๐—ฎ๐—ฟ-๐˜๐—ฒ๐—ฟ๐—บ ๐—ฐ๐—ฎ๐˜๐—ฎ๐—น๐˜†๐˜€๐˜๐˜€ for IBRX.โžค Final efficacy results remain critical; ๐—™๐——๐—” ๐—ฎ๐—ฝ๐—ฝ๐—ฟ๐—ผ๐˜ƒ๐—ฎ๐—น ๐—ถ๐˜€ ๐—ป๐—ผ๐˜ ๐—ด๐˜‚๐—ฎ๐—ฟ๐—ฎ๐—ป๐˜๐—ฒ๐—ฒ๐—ฑ.๐Ÿ‘‰ ๐—˜๐˜…๐—ฝ๐—ฒ๐—ฟ๐˜ ๐—ฆ๐˜๐—ฎ๐˜๐—ฒ๐—บ๐—ฒ๐—ป๐˜:๐—ฃ๐—ฎ๐˜๐—ฟ๐—ถ๐—ฐ๐—ธ ๐—ฆ๐—ผ๐—ผ๐—ป-๐—ฆ๐—ต๐—ถ๐—ผ๐—ป๐—ด, ๐— .๐——., Founder and Executive Chairman of ImmunityBio:"The final analysis of this study will determine whether adding ANKTIVA to BCG improves complete response rates and the durability of those responses when compared with BCG alone,"" datetime: "2026-10-21T11:45:25.000Z" locales: - [en](https://longbridge.com/en/topics/100000000948323.md) - [zh-CN](https://longbridge.com/zh-CN/topics/100000000948323.md) - [zh-HK](https://longbridge.com/zh-HK/topics/100000000948323.md) author: "[Hardik Shah](https://longbridge.com/en/profiles/27423834.md)" generator: "portal-rs" --- # ๐Ÿ“ข ๐—๐—จ๐—ฆ๐—ง ๐—œ๐—ก: $ImmunityBio(IBRX.US) ImmunityBio Complโ€ฆ ### Related Stocks - [IBRX.US](https://longbridge.com/en/quote/IBRX.US.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**